We are Healthy
U.S.

New Biomaterial Coating Protects Transplanted Insulin Cells

A new lab-created coating helps protect donor cells in mice, a potential step toward better type 1 diabetes treatments.

Updated on Oct. 16, 2026 in Diabetes

Isometric editorial illustration showing a microscopic cell protected by a translucent geometric hydrogel shell, representing medical research innovation.
Researchers have created a biomaterial hydrogel coating that shields insulin-producing cells from immune attacks, potentially improving long-term diabetes treatments. AI Illustration. Upload story photo >

Live Poll

Do you trust lab results for medical treatments before they reach human clinical trials?

Researchers have developed a new biomaterial coating modeled after human egg cells that protects transplanted insulin-producing cells from immune attacks. This development could eventually help people with type 1 diabetes manage blood sugar without the need for lifelong immunosuppression.

Why it matters

Currently, transplanting insulin-producing cells often requires patients to take immune-suppressing drugs to prevent the body from rejecting the new tissue. This new coating aims to provide a protective barrier that shields these cells from the immune system while still allowing them to function.

In a study published in Nature Biomedical Engineering, researchers tested a 20-micrometer thick biomaterial coating in immunocompetent diabetic mice. While 80 percent of mice maintained normoglycemia for 66 days, the long-term effectiveness of the material is still being researched.

The players

The Pennsylvania State University

An academic institution where the research team developed the egg-inspired biomaterial coating.

Indian Institute of Science

A public research university that contributed to the study's scientific findings.

The details

The researchers created a hydrogel structure using fibrinogen and alginate, crosslinked with calcium ions and thrombin to mimic the protective zona pellucida of a human egg cell. By applying thrombin directly to the cell membranes, the team triggered the formation of this protective layer. This structure acts as a physical shield that prevents immune cells from attacking the transplanted insulin-producing islets while still allowing for necessary nutrient and insulin exchange.

Timeline

  1. Researchers began exploring donor cell encapsulation methods in the 1980s.

  2. The team spent eight years from 2018 to 2026 finetuning the coating protocol.

  3. In the study, 80 percent of mice maintained normoglycemia for 66 days post-transplantation.

  4. Researchers are currently working to improve the material's therapeutic efficacy beyond 100 days.

Health Landscape

This research follows a long line of efforts to perfect donor cell encapsulation that began in the 1980s. It represents a shift from older, thicker encapsulation methods toward refined, cell-mimicking barriers that aim to replace the need for systemic immunosuppressive therapy.

This finding is currently in a preclinical stage and is not available for clinical use. Patients interested in how emerging transplant technologies might one day change diabetes management should discuss the role of immunosuppression with their endocrinologist.

The takeaway

This study highlights how biomimetic materials may one day solve the immune rejection problems associated with islet cell transplants. Keep an eye on ongoing research in this field for updates on when such technologies might progress to human clinical trials.

Further reading

For more background on the latest developments in cell-based treatments, explore our Diabetes section.

Source note: This article includes information reported by The Scientist.

Live Poll

Do you trust lab results for medical treatments before they reach human clinical trials?